Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Treatment Program for Anemia in AIDS Patients

This study has been completed.
Sponsor:
Information provided by:
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:
NCT00002022
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: February 1991
  Purpose

The objective of the Eprex (erythropoietin) Treatment Program is to provide erythropoietin for the treatment of anemia in AIDS patients.


Condition Intervention
HIV Infections
Cytopenias
Drug: Epoetin alfa

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Treatment Program for Anemia in AIDS Patients

Resource links provided by NLM:


Further study details as provided by NIH AIDS Clinical Trials Information Service:

  Eligibility

Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

  • Life expectancy < 3 months.
  • = or < grade 4 performance score.
  • AIDS-related dementia.
  • Uncontrolled hypertension.
  • Acute symptomatic opportunistic infection or other AIDS-defining illness.

Patients with the following are excluded:

  • Life expectancy < 3 months.
  • = or < grade 4 performance score.
  • AIDS-related dementia.
  • Uncontrolled hypertension.
  • Acute symptomatic opportunistic infection or other AIDS-defining illness.

Patients must have:

  • A clinical diagnosis of AIDS.
  • Hematocrit < 30 percent.
  • Endogenous serum erythropoietin level = or < 500 U/ml.
  • A life expectancy = or > 3 months.
  • > Grade 4 performance score.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002022

Locations
United States, New Jersey
R W Johnson Pharmaceutical Research Institute
Raritan, New Jersey, United States, 088690602
Sponsors and Collaborators
R W Johnson Pharmaceutical Research Institute
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00002022     History of Changes
Other Study ID Numbers: 004G, I88-083
Study First Received: November 2, 1999
Last Updated: June 23, 2005
Health Authority: United States: Food and Drug Administration

Keywords provided by NIH AIDS Clinical Trials Information Service:
Recombinant Proteins
Drugs, Investigational
Erythropoietin
Acquired Immunodeficiency Syndrome
Anemia
Zidovudine

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
RNA Virus Infections
Retroviridae Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Epoetin alfa
Hematinics
Hematologic Agents
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014